Evidence map›Paper›PMID 32648145›Full record

ArticleNeurochemical research2020

Loss of Collapsin Response Mediator Protein 4 Attenuates 6-Hydroxydopamine-Induced Impairments in a Mouse Model of Parkinson's Disease.

Wenting Li, Yoshio Goshima, Toshio Ohshima

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 60% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Wenting LiDepartment of Life Science and Medical Bio-Science, Waseda University, 2-2 Wakamatsu-cho Shinjukuku, Tokyo, 162-8480, Japan.
Yoshio GoshimaDepartment of Molecular Pharmacology and Neurobiology, Yokohama City University Graduate School of Medicine, Yokohama, 236-0004, Japan.
Toshio OhshimaDepartment of Life Science and Medical Bio-Science, Waseda University, 2-2 Wakamatsu-cho Shinjukuku, Tokyo, 162-8480, Japan. ohshima@waseda.jp.ORCID http://orcid.org/0000-0003-4931-7087
Waseda University · JPYokohama City University · JP

Funding

Japan Society for the Promotion of Science 17082006Japan Society for the Promotion of Science 18K06511Japan Society for the Promotion of Science 26430043Japan Society for the Promotion of Science 42890001
6 · The paper itself

Abstract

Parkinson's disease (PD) is a chronic neurodegenerative disorder characterized by impaired motor symptoms induced by the degeneration of dopaminergic neurons of the substantia nigra pars compacta (SNc). Many factors are speculated to operate in the mechanism of PD, including oxidative stress, mitochondrial dysfunction, abnormal protein handling, and PD induced apoptosis. Besides, researchers have recently shown that inflammatory secretions may engage neighboring cells such as astrocytes, which then induce autocrine and paracrine responses that amplify the inflammation, leading to neurodegeneration. In the present study, we analyzed the neuroprotective and anti-inflammatory effects of collapsin response mediator protein 4 (CRMP4) deletion in 6-hydroxydopamine (6-OHDA)-injected male mice, as well as its effects on motor impairments. Our findings indicated that the deletion of CRMP4 could maintain the TH-positive fibers in the striatum and the TH-positive cells in SNc, attenuate the inflammatory responses, and improve motor coordination and rotational behavior. Furthermore, based on our findings at the early time points, we hypothesized that primary differences between the Crmp4+/+ and Crmp4-/- mice may occur in microglia instead of neurons. Although further work should be carried out to clarify the specific role of CRMP4 in the pathogenesis of PD, our findings suggest that it could be a possible target for the treatment of PD.

Indexed as

AnimalsCaspase 3Cyclooxygenase 2Dopaminergic NeuronsGene DeletionGenetic TherapyMaleMiceMicrogliaNerve Tissue ProteinsOxidopamineParkinson Disease, SecondaryPars CompactaPsychomotor DisordersPsychomotor PerformanceCasp3 protein, mouseCaspase 3Cyclooxygenase 2Dpysl3 protein, mouseNerve Tissue ProteinsOxidopaminePtgs2 protein, mouseMouse modelNeurodegenerationNeuroinflammationParkinson's disease

Identifiers

PMID32648145
OpenAlexW3041116448

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.